{"id":45929,"date":"2025-11-05T22:52:09","date_gmt":"2025-11-05T14:52:09","guid":{"rendered":"https:\/\/flcube.com\/?p=45929"},"modified":"2025-11-05T22:52:11","modified_gmt":"2025-11-05T14:52:11","slug":"jiangsu-vcares-vc004-joins-nmpas-spark-oncology-program","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45929","title":{"rendered":"Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program"},"content":{"rendered":"\n<p>The <strong>Center for Drug Evaluation (CDE)<\/strong> under the National Medical Products Administration (NMPA) has officially welcomed <strong>Jiangsu Vcare PharmaTech\u2019s VC004<\/strong>\u2014a next\u2011generation anti\u2011drug\u2011resistance TRK inhibitor\u2014into the <strong>&#8220;Support Anti\u2011Tumor Drugs R&amp;D for Kids (SPARK)&#8221;<\/strong> project. VC004\u2019s marketing application was already approved by the NMPA earlier this year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile\">Product Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class:<\/strong> Category\u202f1 small\u2011molecule, targeted anti\u2011tumor agent.<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Treatment of <strong>adult and adolescent solid\u2011tumor patients<\/strong> (\u226512\u202fyears) carrying a <strong>neurotrophin tyrosine\u2011receptor kinase (NTRK) fusion gene<\/strong>. Suitable for locally advanced, metastatic disease or post\u2011surgical resection scenarios that risk serious complications. Indicated when no satisfactory alternative therapies exist or prior treatments have failed.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SPARK Alignment:<\/strong> Inclusion in the SPARK program signals the NMPA\u2019s commitment to accelerating pediatric oncology research while allowing VC004 to benefit from potential expedited development pathways.<\/li>\n\n\n\n<li><strong>Market Gap:<\/strong> NTRK fusions are rare yet incurable with standard therapies; VC004 offers a novel mechanism of action that could redefine treatment for a previously underserved patient population.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones\">Regulatory Milestones<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Marketing Authorization:<\/strong> Approved by the NMPA in 2025, completing a critical regulatory hurdle.<\/li>\n\n\n\n<li><strong>Future Outlook:<\/strong> With NMPA backing and SPARK designation, VC004 is poised for accelerated clinical development and potential global expansion, positioning Jiangsu Vcare PharmaTech as a key player in precision oncology for children and adolescents.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45932,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[102,14,573],"class_list":["post-45929","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cde","tag-nmpa","tag-vcare-pharmatech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially welcomed Jiangsu Vcare PharmaTech\u2019s VC004\u2014a next\u2011generation anti\u2011drug\u2011resistance TRK inhibitor\u2014into the &quot;Support Anti\u2011Tumor Drugs R&amp;D for Kids (SPARK)&quot; project. VC004\u2019s marketing application was already approved by the NMPA earlier this year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45929\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program\" \/>\n<meta property=\"og:description\" content=\"The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially welcomed Jiangsu Vcare PharmaTech\u2019s VC004\u2014a next\u2011generation anti\u2011drug\u2011resistance TRK inhibitor\u2014into the &quot;Support Anti\u2011Tumor Drugs R&amp;D for Kids (SPARK)&quot; project. VC004\u2019s marketing application was already approved by the NMPA earlier this year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45929\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T14:52:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-05T14:52:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0508.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45929#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45929\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program\",\"datePublished\":\"2025-11-05T14:52:09+00:00\",\"dateModified\":\"2025-11-05T14:52:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45929\"},\"wordCount\":231,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45929#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0508.webp\",\"keywords\":[\"CDE\",\"NMPA\",\"Vcare PharmaTech\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45929#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45929\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45929\",\"name\":\"Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45929#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45929#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0508.webp\",\"datePublished\":\"2025-11-05T14:52:09+00:00\",\"dateModified\":\"2025-11-05T14:52:11+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially welcomed Jiangsu Vcare PharmaTech\u2019s VC004\u2014a next\u2011generation anti\u2011drug\u2011resistance TRK inhibitor\u2014into the \\\"Support Anti\u2011Tumor Drugs R&D for Kids (SPARK)\\\" project. VC004\u2019s marketing application was already approved by the NMPA earlier this year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45929#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45929\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45929#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0508.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0508.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45929#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially welcomed Jiangsu Vcare PharmaTech\u2019s VC004\u2014a next\u2011generation anti\u2011drug\u2011resistance TRK inhibitor\u2014into the \"Support Anti\u2011Tumor Drugs R&D for Kids (SPARK)\" project. VC004\u2019s marketing application was already approved by the NMPA earlier this year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45929","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program","og_description":"The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially welcomed Jiangsu Vcare PharmaTech\u2019s VC004\u2014a next\u2011generation anti\u2011drug\u2011resistance TRK inhibitor\u2014into the \"Support Anti\u2011Tumor Drugs R&D for Kids (SPARK)\" project. VC004\u2019s marketing application was already approved by the NMPA earlier this year.","og_url":"https:\/\/flcube.com\/?p=45929","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-05T14:52:09+00:00","article_modified_time":"2025-11-05T14:52:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0508.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45929#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45929"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program","datePublished":"2025-11-05T14:52:09+00:00","dateModified":"2025-11-05T14:52:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45929"},"wordCount":231,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45929#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0508.webp","keywords":["CDE","NMPA","Vcare PharmaTech"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45929#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45929","url":"https:\/\/flcube.com\/?p=45929","name":"Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45929#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45929#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0508.webp","datePublished":"2025-11-05T14:52:09+00:00","dateModified":"2025-11-05T14:52:11+00:00","description":"The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially welcomed Jiangsu Vcare PharmaTech\u2019s VC004\u2014a next\u2011generation anti\u2011drug\u2011resistance TRK inhibitor\u2014into the \"Support Anti\u2011Tumor Drugs R&D for Kids (SPARK)\" project. VC004\u2019s marketing application was already approved by the NMPA earlier this year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45929#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45929"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45929#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0508.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0508.webp","width":1080,"height":608,"caption":"Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45929#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Vcare\u2019s VC004 Joins NMPA\u2019s SPARK Oncology Program"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0508.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45929"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45929\/revisions"}],"predecessor-version":[{"id":45933,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45929\/revisions\/45933"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45932"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45929"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45929"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}